Ascletis Pharma, Inc. (HK:1672)
:1672
Top Page
Ascletis Pharma, Inc.
(1672)
Select Model
Select Model
Rating:54Neutral
Price Target:
HK$13.50
▼(-20.49% Downside)
Action:ReiteratedDate:12/10/25
Ascletis Pharma's stock score is primarily influenced by its strong technical momentum, despite financial challenges and a difficult valuation. The company's robust balance sheet offers some stability, but ongoing losses and negative cash flow are significant concerns.
Positive Factors
Strong balance sheet
Ascletis’ strong equity ratio and sizable cash reserves provide a multi-quarter buffer against operating losses and support continued R&D and trial execution. Low debt enhances financial flexibility to fund clinical programs without immediate refinancing, preserving strategic optionality.
Negative Factors
Negative cash flow generation
Persistent negative operating and free cash flow indicates Ascletis does not generate sustainable cash from core operations. Continued reliance on reserves or external funding raises dilution and execution risk; sustained burn could force R&D cutbacks or trial delays.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong balance sheet
Ascletis’ strong equity ratio and sizable cash reserves provide a multi-quarter buffer against operating losses and support continued R&D and trial execution. Low debt enhances financial flexibility to fund clinical programs without immediate refinancing, preserving strategic optionality.
Read all positive factors
Ascletis Pharma, Inc. (1672) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$18.02B
Dividend YieldN/A
Average Volume (3M)8.30M
Price to Earnings (P/E)―
Beta (1Y)0.90
Revenue Growth-76.58%
EPS Growth-4.90%
CountryHK
Employees231
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.32
Shares Outstanding1,068,214,500
10 Day Avg. Volume6,104,199
30 Day Avg. Volume8,303,348
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)1.44
Price to Sales (P/S)2206.93
P/FCF Ratio-8.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$23.86Price Target Upside40.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.9
Revenue Forecast (FY)HK$1.29B
Ascletis Pharma, Inc. Business Overview & Revenue Model
Company Description
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. The company offers Ritonavir oral tablet, a pharmacokinetic ...
How the Company Makes Money
Ascletis Pharma generates revenue through multiple streams, primarily from the commercialization of its proprietary drug products, including antiviral treatments for hepatitis and cancer therapies. The company also engages in strategic partnership...
Ascletis Pharma, Inc. Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
70
Positive
Cash Flow
40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.36M | 1.28M | 56.60M | 54.09M | 76.88M | 35.00M |
| Gross Profit | 856.00K | 735.00K | 25.99M | -24.69M | 39.17M | -23.50M |
| EBITDA | -408.21M | -390.45M | -126.09M | -284.50M | -169.35M | -181.94M |
| Net Income | -258.57M | -300.94M | -144.72M | -314.84M | -199.02M | -209.24M |
Balance Sheet | ||||||
| Total Assets | 2.00B | 2.12B | 2.49B | 2.66B | 2.83B | 3.07B |
| Cash, Cash Equivalents and Short-Term Investments | 1.80B | 1.95B | 2.30B | 2.48B | 2.50B | 2.71B |
| Total Debt | 4.27M | 7.63M | 8.42M | 4.24M | 2.75M | 1.59M |
| Total Liabilities | 129.00M | 158.41M | 148.94M | 117.16M | 100.89M | 85.42M |
| Stockholders Equity | 1.87B | 1.97B | 2.34B | 2.54B | 2.73B | 2.98B |
Cash Flow | ||||||
| Free Cash Flow | -313.25M | -343.73M | -163.32M | -156.85M | -154.13M | -123.87M |
| Operating Cash Flow | -311.15M | -341.58M | -144.16M | -142.45M | -146.93M | -84.91M |
| Investing Cash Flow | 1.62B | 978.91M | 149.84M | -1.30B | -274.49M | 132.30M |
| Financing Cash Flow | -72.54M | -103.51M | -81.50M | -1.42M | -31.10M | -21.67M |
Ascletis Pharma, Inc. Technical Analysis
Positive
16.98
Price Trends
15.07
Positive
14.05
Positive
12.59
Positive
Market Momentum
0.47
Negative
63.54
Neutral
84.13
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1672, the sentiment is Positive. The current price of 16.98 is above the 20-day moving average (MA) of 15.24, above the 50-day MA of 15.07, and above the 200-day MA of 12.59, indicating a bullish trend. The MACD of 0.47 indicates Negative momentum. The RSI at 63.54 is Neutral, neither overbought nor oversold. The STOCH value of 84.13 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1672.
Ascletis Pharma, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | HK$27.73B | 34.57 | 25.67% | ― | 2.57% | 18.79% | |
54 Neutral | HK$18.02B | -22.61 | -12.74% | ― | -76.58% | -4.90% | |
53 Neutral | HK$10.63B | -77.24 | -11.84% | ― | 1219.19% | 25.15% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | HK$1.96B | -3.21 | -184.99% | ― | ― | -18.99% | |
40 Underperform | HK$11.43B | 30.77 | 24.17% | ― | 240.05% | -140.09% |
* Healthcare Sector Average
HK:1672
Ascletis Pharma, Inc.
16.98
12.03
243.03%
HK:2157
Lepu Biopharma Co. Ltd. Class H
6.15
2.89
88.65%
HK:2171
CARsgen Therapeutics Holdings Ltd.
18.39
7.51
69.03%
HK:2179
Jiangsu Recbio Technology Co., Ltd. Class H
4.10
-2.90
-41.43%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
76.60
49.85
186.36%
HK:6955
Shandong Boan Biotechnology Company., Limited. Class H
6.98
-1.10
-13.61%
Ascletis Pharma, Inc. Corporate Events
Ascletis Pharma to Raise HK$835 Million via Share Placement to Fund Obesity Drug Trials
Feb 2, 2026
Ascletis Pharma Inc. has entered into a placing agreement to issue 69,256,000 new shares, representing about 6.98% of its existing share capital, at HK$12.18 per share to at least six institutional and other independent investors, at a discount to...
Ascletis Reports Positive Long-Term Phase III Safety Data for First-in-Class Oral Acne Drug Denifanstat
Jan 29, 2026
Ascletis Pharma has reported positive topline data from a Phase III open-label, multicenter study in China evaluating its first-in-class, once-daily oral fatty acid synthase inhibitor denifanstat (ASC40) in 240 patients with moderate-to-severe acn...
Ascletis Starts U.S. Phase II Diabetes Trial of Oral GLP-1 Drug ASC30 After Strong Obesity Data
Jan 26, 2026
Ascletis Pharma has begun dosing the first participants in a 13-week, randomized Phase II trial in the U.S. to evaluate its oral small molecule GLP-1 receptor agonist ASC30 for the treatment of type 2 diabetes, with topline data expected in the th...
Ascletis Advances Next-Generation Once-Monthly Triple Agonist ASC37 for Obesity Into Clinical Pathway
Jan 20, 2026
Ascletis Pharma has selected ASC37, a next-generation, once‑monthly, subcutaneously administered GLP‑1R/GIPR/GCGR triple peptide agonist, as a clinical development candidate for obesity and plans to file an Investigational New Drug app...
Ascletis Wins FDA Green Light for Phase II U.S. Diabetes Trial of Oral GLP-1 Drug ASC30
Jan 5, 2026
Ascletis Pharma has received U.S. FDA Investigational New Drug clearance to launch a 13-week Phase II clinical trial of its oral small molecule GLP-1 receptor agonist ASC30 in participants with type 2 diabetes, with enrollment of about 100 U.S. pa...
Ascletis Pharma Upsizes Share Repurchase to HK$500 Million Amid Drug Development Success
Dec 16, 2025
Ascletis Pharma Inc. has announced an increase in its share repurchase program from HK$300 million to HK$500 million, citing the undervaluation of its stock and significant recent achievements in drug development. The company aims to enhance share...
Ascletis Pharma Reports Positive Phase I Results for ASC50
Dec 15, 2025
Ascletis Pharma Inc. announced positive topline results from its U.S. Phase I study of ASC50, an oral small molecule IL-17 inhibitor. The study demonstrated that ASC50 is safe, well-tolerated, and exhibits a dose-proportional pharmacokinetic profi...
Ascletis Pharma’s Acne Treatment Drug Application Accepted by China NMPA
Dec 10, 2025
Ascletis Pharma Inc. announced that the China National Medical Products Administration has accepted its New Drug Application for denifanstat (ASC40), a first-in-class fatty acid synthase inhibitor for treating moderate-to-severe acne vulgaris. Thi...
Ascletis Pharma’s ASC30 Shows Promising Results in Obesity Treatment Study
Dec 8, 2025
Ascletis Pharma Inc. announced positive results from its 13-week Phase II study of ASC30, an oral GLP-1 receptor agonist for obesity treatment. The study demonstrated significant weight loss and improved gastrointestinal tolerability compared to p...
Ascletis Pharma Advances ASC37 for Obesity Treatment
Nov 30, 2025
Ascletis Pharma Inc. has announced the selection of its first oral GLP-1R/GIPR/GCGR triple peptide agonist, ASC37, for clinical development. This drug candidate, developed using Ascletis’ proprietary technologies, has shown significantly hig...
Ascletis Pharma Advances Obesity Treatment with New Co-Formulation
Nov 12, 2025
Ascletis Pharma Inc. has announced the co-formulation of ASC36, an amylin receptor agonist, and ASC35, a GLP-1R/GIPR dual agonist, both designed for once-monthly subcutaneous administration. The co-formulation demonstrated significant body weight ...
Ascletis Pharma Unveils Promising Obesity Treatment Results at ObesityWeek 2025
Nov 5, 2025
Ascletis Pharma Inc. announced promising results from its Phase Ib studies of ASC30, both as an oral tablet and a subcutaneous injection, along with a preclinical study of a combination therapy involving ASC31 and ASC47. The oral tablet showed up ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.